VHL and von Hippel-Lindau disease: Longer term, the identification of tumour biomarkers that might distinguish between VHL-related and VHL disease-independent haemangioblastomas [22] could enable better stratification of sporadic haemangioblastoma patients and a more personalized approach to continuing surveillance.